Evidence map›Paper›PMID 37644057›Full record

ArticleNature communications2023

Publisher Correction: High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation.

Brooke D Huisman, Ning Guan, Timo Rückert, Lee Garner, Nishant K Singh, Andrew J McMichael, Geraldine M Gillespie, Chiara Romagnani, Michael E Birnbaum

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Brooke D Huisman *Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Ning Guan *Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0522-7792
Timo RückertInnate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Leibniz Institut, Berlin, Germany.ORCID http://orcid.org/0000-0003-1433-1372
Lee GarnerCentre for Immuno-Oncology, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nishant K SinghKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Andrew J McMichaelCentre for Immuno-Oncology, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9101-7478
Geraldine M GillespieCentre for Immuno-Oncology, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1075-870X
Chiara RomagnaniInnate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Leibniz Institut, Berlin, Germany.ORCID http://orcid.org/0000-0002-5167-7463
Michael E BirnbaumKoch Institute for Integrative Cancer Research, Cambridge, MA, USA. mbirnb@mit.edu.ORCID http://orcid.org/0000-0002-2281-3518
University of Oxford · GBGerman Rheumatism Research Centre · DEIIT@MIT · USRagon Institute of MGH, MIT and Harvard · US

Funding

Graduate Training in Computational and Systems BiologyT32GM087237 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2009 to 2023
$4.6M
NIGMS NIH HHS T32 GM087237
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37644057
PMCPMC10465582
OpenAlexW4386255010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.